Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 15/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19953906 | 1.00 | PDK2 (0.41) | PDK2ALDH1A1CES2BCHEGAA | |
| SCHEMBL21578531 | 0.94 | PDK2 (0.38) | PDK2ALDH1A1CES2BCHEGAA | |
| SCHEMBL24293093 | 0.93 | PDK2 (0.43) | PDK2ALDH1A1NPSR1 | |
| SCHEMBL22595642 | 0.92 | PDK2 (0.48) | PDK2PGRCYP1A2 | |
| SCHEMBL17197536 | 0.91 | PDK2 (0.43) | PDK2NPSR1 | |
| SCHEMBL808381 | 0.90 | PDK2 (0.40) | PDK2 | |
| SCHEMBL21394194 | 0.89 | PDK2 (0.40) | PDK2ALDH1A1ADAMTS5 | |
| SCHEMBL21394191 | 0.89 | PDK2 (0.40) | PDK2ALDH1A1ADAMTS5 | |
| SCHEMBL24905091 | 0.89 | PDK2 (0.40) | PDK2 | |
| SCHEMBL24904840 | 0.89 | PDK2 (0.40) | PDK2NPSR1ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177303-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-06-13 | — | — | US | disclosed |
| US-9917270-B1 | Organic electroluminescent device having an exciton quenching layer | CYNORA GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| US-9917270-B1 | Organic electroluminescent device having an exciton quenching layer | CYNORA GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177303-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OR10J3, ORC3, OR51E2 | PDK2 4139/4885ALDH1A1 542/4885CES2 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.